Lilly Buys Merida Biosciences in $2.9B Autoimmune Bet

Media partner

PHARMA · IMMUNOLOGY & INFLAMMATION · SEPTEMBER 12, 2026 · UNITED STATES

Thirteen acquisitions into 2026, Eli Lilly has committed up to $2.9 billion to acquire Merida Biosciences, a privately held biotechnology company developing a precision platform designed to selectively eliminate the disease-causing autoantibodies implicated in autoimmune and allergic conditions, according to Lilly’s announcement on August 31. The deal is the company’s third immunology-focused acquisition this year and adds a mechanistic approach that differs from conventional broad immunosuppression.

Merida’s lead asset, MER511, is in Phase 1 clinical development for Graves disease — a condition in which the immune system attacks the thyroid gland — and for thyroid eye disease (TED), a related disorder, per the company’s announcement. A second candidate, MER769, targets food allergy, asthma, and other allergic diseases and remains at an earlier stage. Merida also maintains programs in renal disease and other immune-mediated conditions, according to Lilly’s press materials, though those programs have not been detailed publicly.

The total deal value of up to approximately $2.9 billion — reported by BioPharma Dive as ‘nearly $2.9 billion’ and by Valor Econômico as ‘up to $2.87 billion’ — comprises an undisclosed upfront payment plus contingent milestone payments. Lilly has not disclosed the upfront figure, meaning the financial exposure at signing is not publicly established. The transaction is expected to close in the fourth quarter of 2026, per the company’s statement.

A platform bet, not a near-term revenue play

MER511’s Phase 1 status is the most consequential fact for investors assessing the deal’s risk profile. Phase 1 trials test safety and dosing in a small number of participants; efficacy data sufficient to support regulatory filings is typically years away. Lilly is paying a headline figure of up to $2.9 billion for a platform whose clinical validation remains limited. Francisco Ramírez-Valle, Lilly’s senior vice president of immunology research and early clinical development, said in the company’s announcement that Lilly is ‘building our portfolio of products around therapies that significantly alter the course of disease, and not just its resulting effects’ — a framing that positions the acquisition as a long-duration pipeline investment rather than a near-term commercial one.

The Merida deal is the third in a sequence of immunology acquisitions Lilly has executed in 2026. In January, the company acquired Ventyx Biosciences for approximately $1.2 billion, gaining experimental NLRP3 (NOD-like receptor protein 3) inflammasome inhibitors, per BioPharma Dive. In February, it agreed to buy Orna Therapeutics for up to $2.4 billion, adding circular RNA-based therapies with potential applications in oncology and immunology, according to Reuters. Each deal targets a distinct molecular mechanism, which may suggest a deliberate effort to assemble non-overlapping platform capabilities rather than concentrate on a single immunological pathway.

Lilly’s total 2026 acquisition spend has surpassed $31 billion across 13 deals, according to Exame, which published a full transaction table on September 1. Bloomberg reported in May that Lilly had committed more than $20 billion to acquisitions by that point; the figure has grown substantially since. The pace is, according to BioPharma Dive’s own M&A tracker, the highest among Lilly’s pharmaceutical peers in 2026.

The competitive and clinical landscape Merida enters

Lilly noted in its announcement that multiple treatments exist for Graves disease and TED, but characterized the current standard of care as addressing symptoms rather than the underlying autoimmune mechanism. The company has not named specific incumbent therapies or identified which products MER511 would compete against if it reaches the market. No analyst estimate of the addressable market for autoantibody-targeting therapies in Graves disease has been published in the sources reviewed for this article.

BMO Capital Markets analyst Evan Seigerman, commenting on the earlier Orna acquisition in Reuters, flagged that circular RNA technology ‘is high-risk and without validation in large trials’ and noted ‘stiff competition from Bristol Myers Squibb’ in the relevant space — a read that applies, at least in part, to the broader immunology platform-acquisition strategy Lilly is pursuing. No analyst commentary specific to the Merida deal was available in the sources reviewed.

The mechanism Merida is developing — binding to and tagging disease-causing autoantibodies for destruction — is described by Lilly as a ‘precise approach’ that targets the biological cause of immune disease rather than broadly suppressing immune function. Whether that precision translates into a clinical or commercial advantage over existing therapies cannot be established from Phase 1 data alone; the company has not published efficacy results from MER511 trials.

On the Latin American regulatory pathway: neither Agência Nacional de Vigilância Sanitária (ANVISA) in Brazil, Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) in Mexico, nor Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) in Argentina has a filing or approval on record for MER511 or MER769, which is expected given the assets’ early-stage status. Any regional regulatory pathway would depend on Phase 2 and Phase 3 data that does not yet exist.

On the payer side, no coverage decision, formulary review, or national procurement process has been initiated for Merida’s assets, consistent with their pre-commercial stage. Payer engagement for a Phase 1 asset is not a near-term operational requirement.

The structural tension in Lilly’s 2026 acquisition program is that its financial capacity — generated by Zepbound and Mounjaro, its obesity and diabetes medicines — is being deployed into assets whose value will be determined by clinical events that are, in most cases, five to ten years away. The milestone-heavy deal structures spread that risk, but they also mean that the $31 billion headline figure overstates the capital already committed. What Lilly has purchased, in Merida as in several other 2026 deals, is optionality — the right to participate in a mechanism if it proves out, at a price set before the proof exists.